Recent Updates
Recently added Catalysts

Non-Hodgkin's Lymphoma: 7 biotech companies competing in the clinic

OncologyKnife fightData as of 2026-09-04

Competitors7in the clinic
Median market cap$239Muniverse median $1.20B
Allocated capital$1.7B$12.1B competing
Phase 3 or filed02 mid, 5 early
Pure plays0this indication only
Capital rank112/299crowding rank 21

Non-Hodgkin's Lymphoma is one of the more crowded fields on the map: 7 companies in the clinic, ranking it 21st of 299 indications by competitor count. The median competitor is worth $239M, below the $1.20B median of the universe.

That gap is the crowding discount. When a field is deep the market pays less per company, because the same eventual revenue has to be split across more shots on goal.

IBRX carries 72% of the $12.1B competing here, more than the other 6 companies combined.

$1.7B of allocated capital sits in Non-Hodgkin's Lymphoma, ranking it 112th of 299 indications by the money committed to it.

Companies developing drugs for Non-Hodgkin's Lymphoma 7

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
IBRXImmunityBioN-803Phase 24$8.7BNo12 31 Dec 2026
ADCTADC TherapeuticsLoncastuximab Tesirine and AcalabrutinibPhase 25$168MNo5 31 Dec 2026
CGEMCullinan TherapeuticsCLN-978Phase 11$1.4BNo8 14 Sep 2026
SANASana BiotechnologySC262Phase 12$1.2BNo2 31 Dec 2026
CLLSCellectis S.A.UCART20x22Phase 12$239MNo3 31 Dec 2026
DTILPrecision BioSciencesPIC1Phase 11$203MNo16 31 Dec 2026
NKTXNkartaNKX019Phase 11$200MNo4 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. IBRX holds 72% of the $12.1B competing in this indication.

Why Non-Hodgkin's Lymphoma is a knife fight

Crowded and cheaply priced. Six or more competitors and a median company below the universe median.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Non-Hodgkin's Lymphoma has 7 competitors and a median of $239M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Desmoid Tumor1 company · $1.5B · median $3.1BUncontestedIntrahepatic Cholangiocarcinoma1 company · $1.5B · median $6.1BUncontestedGastrointestinal Cancer1 company · $1.5B · median $6.1BUncontestedSystemic Mastocytosis1 company · $1.5B · median $6.1BUncontestedSoft-tissue Sarcoma2 companies · $1.5B · median $4.0BConcentrated betBRAF V600 Mutated Melanoma1 company · $1.9B · median $5.7BUncontestedMetastatic Solid Tumors1 company · $1.9B · median $5.7BUncontestedUrothelial Cancer1 company · $1.4B · median $1.4BUncontested

Non-Hodgkin's Lymphoma pipeline questions

Which biotech companies are developing drugs for Non-Hodgkin's Lymphoma?

7 US-listed companies in the $100M to $20B market cap band run clinical programmes in Non-Hodgkin's Lymphoma. The largest and most advanced are ImmunityBio (IBRX, N-803, Phase 2); ADC Therapeutics (ADCT, Loncastuximab Tesirine and Acalabrutinib, Phase 2); Cullinan Therapeutics (CGEM, CLN-978, Phase 1); Sana Biotechnology (SANA, SC262, Phase 1); Cellectis S.A. (CLLS, UCART20x22, Phase 1). The full list of 7 is in the table on this page.

How advanced is the Non-Hodgkin's Lymphoma pipeline?

Of the 7 clinical-stage programmes in Non-Hodgkin's Lymphoma, 0 are in Phase 3 or filed, 2 are in mid-stage development and 5 are in early-stage development.

Which company leads the Non-Hodgkin's Lymphoma field?

IBRX is the largest developer in Non-Hodgkin's Lymphoma, holding 72% of the $12.1B of market capitalisation competing in the indication. The median competitor is worth $239M.

When is the next Non-Hodgkin's Lymphoma catalyst?

The next dated catalyst in Non-Hodgkin's Lymphoma is CGEM on 14 Sep 2026. 7 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map